Tema Oncology ETF (CANC) belongs to the Health & Biotech Equities category. Below you'll find alternative ETFs from the same category, ranked by key criteria, plus funds that investors commonly compare with CANC. Use the tables to find lower-cost options, better risk-adjusted returns, or a closer substitute for your current allocation.
Cheapest Alternatives to CANC
CANC charges 0.75% annually. There are 46 ETFs in the Health & Biotech Equities category with lower expense ratios, going as low as 0.08%.
| Symbol | Name | Expense Ratio | AUM | Inception | |
|---|---|---|---|---|---|
| Fidelity MSCI Health Care Index ETF | 0.08% | 2.99B | Oct 2013 | CANC vs FHLC | |
| State Street Health Care Select Sector SPDR ETF | 0.08% | 38.47B | Dec 1998 | CANC vs XLV | |
| Vanguard Health Care ETF | 0.09% | 19.00B | Jan 2004 | CANC vs VHT | |
| Portfolio Building Block World Pharma and Biotech ... | 0.13% | 9.98M | Nov 2025 | CANC vs PBPH | |
| GSK plc ADRhedged ETF | 0.19% | 793.18K | Jan 2025 | CANC vs GSKH |
Best Risk-Adjusted Alternatives to CANC
CANC has a PortfoliosLab risk / return rank of 85. There are 9 ETFs in the Health & Biotech Equities category with higher risk-adjusted ranks, going as high as 95.
| Symbol | Name | Risk / Return Rank | AUM | Inception | |
|---|---|---|---|---|---|
| Virtus LifeSci Biotech Clinical Trials ETF | 95 | 40.93M | Dec 2014 | CANC vs BBC | |
| ALPS Medical Breakthroughs ETF | 92 | 160.12M | Dec 2014 | CANC vs SBIO | |
| SPDR S&P Biotech ETF | 90 | 8.62B | Feb 2006 | CANC vs XBI | |
| iShares Neuroscience and Healthcare ETF | 89 | 5.39M | Aug 2022 | CANC vs IBRN | |
| First Trust Nasdaq Pharmaceuticals ETF | 87 | 33.60M | Sep 2016 | CANC vs FTXH |
Top Performing CANC Alternatives (YTD)
CANC is at 11.49% YTD. There are 18 ETFs in the Health & Biotech Equities category with higher YTD returns, going as high as 27.05%.
| Symbol | Name | YTD Return | AUM | Inception | |
|---|---|---|---|---|---|
| Roundhill UNH WeeklyPay ETF | 27.05% | 4.79M | Dec 2025 | CANC vs UNHW | |
| Virtus LifeSci Biotech Clinical Trials ETF | 25.75% | 40.93M | Dec 2014 | CANC vs BBC | |
| AdvisorShares Psychedelics ETF | 25.04% | 33.07M | Sep 2021 | CANC vs PSIL | |
| ARK Genomic Revolution Multi-Sector ETF | 24.30% | 1.31B | Oct 2014 | CANC vs ARKG | |
| SPDR S&P Biotech ETF | 20.70% | 8.62B | Feb 2006 | CANC vs XBI |
Lowest Volatility Alternatives to CANC
CANC has 22.72% 1-year volatility. There are 45 ETFs in the Health & Biotech Equities category with lower 1-year volatility, going as low as 0.00%.
| Symbol | Name | Volatility 1Y | AUM | Inception | |
|---|---|---|---|---|---|
| Loncar Cancer Immunotherapy ETF | 0.00% | 12.73M | Oct 2015 | CANC vs CNCR | |
| Amplify Treatments, Testing and Advancements ETF | 0.00% | 9.68M | Jun 2020 | CANC vs GERM | |
| Horizon Kinetics SPAC Active ETF | 8.65% | 10.10M | Jun 2007 | CANC vs SPAQ | |
| State Street Health Care Select Sector SPDR Premiu... | 11.06% | 14.95M | Jul 2025 | CANC vs XLVI | |
| Global X Aging Population ETF | 13.70% | 80.19M | May 2016 | CANC vs AGNG |
Lowest Drawdown Alternatives to CANC
CANC has a 1-year max drawdown of -9.30%. There are 7 ETFs in the Health & Biotech Equities category with shallower 1-year drawdowns, going as shallow as 0.00%.
| Symbol | Name | Max Drawdown 1Y | AUM | Inception | |
|---|---|---|---|---|---|
| Amplify Treatments, Testing and Advancements ETF | 0.00% | 9.68M | Jun 2020 | CANC vs GERM | |
| Horizon Kinetics SPAC Active ETF | -5.00% | 10.10M | Jun 2007 | CANC vs SPAQ | |
| First Trust Nasdaq Pharmaceuticals ETF | -7.47% | 33.60M | Sep 2016 | CANC vs FTXH | |
| Invesco Nasdaq Biotechnology ETF | -8.34% | 68.94M | Jun 2021 | CANC vs IBBQ | |
| iShares U.S. Pharmaceuticals ETF | -8.47% | 956.44M | May 2006 | CANC vs IHE |
Other ETFs from Tema
The 7 most viewed Tema ETFs shown here include VOLT, RSHO, NASA and span 9 categories. AUM among these funds goes as high as $1B.
| Symbol | Name | Category | Risk / Return Rank | YTD Return | AUM | Inception | |
|---|---|---|---|---|---|---|---|
| Tema Electrification ETF | Global Equities | 89 | 40.29% | 693.48M | Dec 2024 | CANC vs VOLT | |
| Tema American Reshoring ETF | Mid Cap Blend Equities | — | — | 302.20M | May 2023 | CANC vs RSHO | |
| Tema Space Innovators ETF | Aerospace & Defense, Actively Managed | — | — | 1.25B | Mar 2026 | CANC vs NASA | |
| Tema Obesity & Cardiometabolic ETF | Health & Biotech Equities | 48 | -1.45% | 51.51M | Nov 2023 | CANC vs HRTS | |
| Tema Monopolies and Oligopolies ETF | Large Cap Growth Equities | 42 | 14.33% | 46.67M | May 2023 | CANC vs TOLL | |
| Tema S&P 500 Historical Weight ETF Strategy | Large Cap Blend Equities, S&P 500 | 73 | 11.15% | 980.79M | Mar 2025 | CANC vs DSPY | |
| Tema International Durable Quality ETF | Foreign Large Cap Equities | — | 0.58% | — | Sep 2025 | CANC vs ITOL |
Often Compared With CANC
Investors most often compare CANC with IYH, VOO, JNJ. These 20 comparison targets span 3 categories, based on PortfoliosLab usage data.
Compare CANC with Any Fund or Stock
Compare CANC with any ETF, mutual fund, or stock using PortfoliosLab's comparison tool.
Pair CANC with funds that move differently
Tema Oncology ETF alternatives help with substitution. Diversifiers are the next step when you want funds with lower historical correlation to CANC.
Explore CANC Diversifiers